Lantern Pharma Inc. - Special Call Transcript
Okay. Good afternoon, everybody. I'm Nicole Leber with Investor Relations at Lantern Pharma and welcome to our Brain Tumor Awareness Month, GPM key opinion leader Webinar. May is bringing tumor awareness month, among dedicated to supporting empowering and amplifying the voice of the brain tumor community. According to braintumor.org, an estimated 700,000 Americans are living with a primary brain tumor and an additional 88,970 people will be diagnosed with the primary brain tumor in 2022. Additionally, the 5-year relative survival rate for all malignant brain tumors is only 35.6%. For today's KOL webinar will be focusing heavily on the primary brain tumor glioblastoma, which is the most common malignant brain tumor among adults with an estimated 13,000 patients diagnosed per year in the United States. In addition to being one of the most common primary cancers, it is one of the most deadly with an average median survival of 15, 16 months. Several of our panels today are experts in the treatment and research of cures
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
